Clinical trial
Impact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial
NCT06213168 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- August 19, 2025
- Completion date
- March 31, 2027
- Enrollment
- 1,084 (estimated)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.
de novo hypoxemic acute respiratory failure (harf)